GFPT2

Across TCGA pan-cancer cohorts, GFPT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GFPT2 data layer compared with 27 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GFPT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GFPT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where GFPT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.284	0.915	<.001	62	view →
GBM	DFS	Tertile	All	0.585	0.896	<.001	23	view →
LUAD	OS	Quartile	II,III,IV	0.304	0.871	.010	10	view →
PDAC	DFS	Median	All	0.348	0.550	.013	4	view →
UCEC	DFS	Median	All	1.000	0.929	.040	2	view →
HNSC	DFS	Quartile	III,IV	0.716	0.921	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GFPT2–CCRCC (DFS)

Open the CCRCC breakdown →